Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Nivolumab vs Sorafenib in First-Line Advanced Hepatocellular Carcinoma
2015-002740-13Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2015-002740-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002740-13.